Anti-saccharomyces cerevisiae antibodies status is associated with oral involvement and disease severity in crohn disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 48, Issue 2, 2009, Pages 161-167

  Russell, R K ^a   Ip, B ^c   Aldhous, M C ^c   MacDougall, M ^d   Drummond, H E ^c   Arnott, I D R ^c   Gillett, P M ^e   McGrogan, P ^a   Weaver, L T ^b   Bisset, W M ^f   Mahdi, G ^f   Wilson, D C ^c   Satsangi, J ^c  

^a ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^f ROYAL ABERDEEN CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

Anti Saccharomyces cerevisiae antibodies; Crohn disease; Early onset; Indeterminate colitis; Ulcerative colitis

Indexed keywords

C REACTIVE PROTEIN; FUNGUS ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; SACCHAROMYCES CEREVISIAE ANTIBODY; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ANTIBODY TITER; ARTICLE; CHILD; CONTROLLED STUDY; CROHN DISEASE; DISEASE MARKER; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRANULOMA; HUMAN; HYPOALBUMINEMIA; INDETERMINATE COLITIS; MAJOR CLINICAL STUDY; MALE; MOUTH DISEASE; PHENOTYPE; PRIORITY JOURNAL; SCHOOL CHILD; ULCERATIVE COLITIS; ADOLESCENT; BLOOD; CASE CONTROL STUDY; EPIDEMIOLOGY; GENOTYPE; HEALTH STATUS; HOSPITALIZATION; IMMUNOLOGY; MICROBIOLOGY; MULTIVARIATE ANALYSIS; PATHOLOGY; RISK; SACCHAROMYCES CEREVISIAE;

SACCHAROMYCES CEREVISIAE;

ADOLESCENT; ANTIBODIES, FUNGAL; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHILD; COLITIS, ULCERATIVE; CROHN DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HEALTH STATUS; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MALE; MULTIVARIATE ANALYSIS; ODDS RATIO; SACCHAROMYCES CEREVISIAE; SEROEPIDEMIOLOGIC STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 66149106326     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e318183e112     Document Type: Article

References (55)

1. Kim SC, Ferry GD. Inflammatory bowel diseases in pediatric and adolescent patients: clinical, therapeutic, and psychosocial considerations. Gastroenterology 2004;126:1550-60.
2. Armitage E, Drummond H, Ghosh S, et al. Incidence of juvenile-onset Crohn's disease in Scotland. Lancet 1999;353:1496-7.
3. Armitage E, Drummond HE, Wilson DC, et al. Increasing incidence of both juvenile-onset Crohn's disease and ulcerative colitis in Scotland. Eur J Gastroenterol Hepatol 2001;13:1439-47.
4. Barton JR, Gillon S, Ferguson A. Incidence of inflammatory bowel disease in Scottish children between 1968 and 1983: marginal fall in ulcerative colitis, three-fold rise in Crohn's disease. Gut 1989;30:618-22.
5. Baron S, Turck D, Leplat C, et al. Environmental risk factors in paediatric inflammatory bowel diseases: a population based case control study. Gut 2005;54:357-63.
6. Gaya DR, Russell RK, Nimmo ER, et al. New genes in inflammatory bowel disease: lessons for complex diseases? Lancet 2006;367:1271-84.
7. Economou M, Trikalinos TA, Loizou KT, et al. Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis. Am J Gastroenterol 2004;99:2393- 404.
8. Russell RK, Drummond HE, Nimmo ER, et al. Genotype-phenotype analysis in childhood-onset Crohn's disease: NOD2/ CARD15 variants consistently predict phenotypic characteristics of severe disease. Inflamm Bowel Dis 2005;11:955-64.
9. Van Limbergen J, Russell RK, Nimmo ER, et al. The genetics of inflammatory bowel disease. Am J Gastroenterol 2007;102:2820- 31.
10. Broberger O, Perlmann P. Demonstration of an epithelial antigen in colon by means of fluorescent antibodies from children with ulcerative colitis. J Exp Med 1962;115:13-26.
11. Perlmann P, Broberger O. Auto-antibodies against antigen derived from colon in the microsomes of regional colonic lymph glands in human ulcerative colitis. Nature 1960;188:749-51.
12. Main J, McKenzie H, Yeaman GR, et al. Antibody to Sacchar-omyces cerevisiae (bakers' yeast) in Crohn's disease. BMJ 1988;297:1105-6.
13. Ruemmele FM, Targan SR, Levy G, et al. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology 1998;115:822-9.
14. Hoffenberg EJ, Fidanza S, Sauaia A. Serologic testing for inflammatory bowel disease. J Pediatr 1999;134:447-52.
15. Forcione DG, Rosen MJ, Kisiel JB, et al. Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease. Gut 2004;53:1117-22.
16. Walker LJ, Aldhous MC, Drummond HE, et al. Anti-Saccharo-myces cerevisiae antibodies (ASCA) in Crohn's disease are associated with disease severity but not NOD2/CARD15 mutations. Clin Exp Immunol 2004;135:490-6.
17. Zholudev A, Zurakowski D, Young W, et al. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am J Gastroenterol 2004;99: 2235-41.
18. Louis E, Michel V, Hugot JP, et al. Early development of stricturing or penetrating pattern in Crohn's disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype. Gut 2003;52:552-7.
19. Arnott ID, Landers CJ, Nimmo EJ, et al. Sero-reactivity to micro-bial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol 2004;99:2376-84.
20. Annese V, Lombardi G, Perri F, et al. Variants of CARD15 are associated with an aggressive clinical course of Crohn's disease-an IG-IBD study. Am J Gastroenterol 2005;100:84-92.
21. Israeli E, Grotto I, Gilburd B, et al. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut 2005;54:1232-6.
22. Seibold F. ASCA: genetic marker, predictor of disease, or marker of a response to an environmental antigen? Gut 2005;54: 1212-3.
23. Cruyssen BV, Peeters H, Hoffman IE, et al. CARD15 polymorphisms are associated with anti-Saccharomyces cerevisiae antibodies in Caucasian Crohn's disease patients. Clin Exp Immunol 2005;140: 354-9.
24. Esters N, Pierik M, van Steen K, et al. Transmission of CARD15 (NOD2) variants within families of patients with inflammatory bowel disease. Am J Gastroenterol 2004;99:299-305.
25. Abreu MT, Taylor KD, Lin YC, et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology 2002;123:679-88.
26. Peeters M, Joossens S, Vermeire S, et al. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoan-tibodies in inflammatory bowel disease. Am J Gastroenterol 2001;96:730-4.
27. Targan SR, Landers CJ, Yang H, et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology 2005;128:2020-8.
28. Mow WS, Vasiliauskas EA, Lin YC, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 2004;126:414-24.
29. Dotan I, Fishman S, Dgani Y, et al. Antibodies against laminaribio-side and chitobioside are novel serologic markers in Crohn's disease. Gastroenterology 2006;131:366-78.
30. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989;170:2-6.
31. Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000;6:8-15.
32. Russell RK, Drummond HE, Nimmo ER, et al. Analysis of the influence of OCTN1/2 variants within the IBD5 locus on disease susceptibility and growth indices in early onset inflammatory bowel disease. Gut 2006;55:1114-23.
33. Russell RK, Drummond HE, Nimmo ER, et al. The contribution of the DLG5 113A variant in early-onset inflammatory bowel disease. J Pediatr 2007;150:268-73.
34. Harty S, Fleming P, Rowland M, et al. A prospective study of the oral manifestations of Crohn's disease. Clin Gastroenterol Hepatol 2005;3:886-91.
35. Sawczenko A, Sandhu BK. Presenting features of inflammatory bowel disease in Great Britain and Ireland. Arch Dis Child 2003;88:995-1000.
36. Van Limbergen J, Russell RK, Nimmo ER, et al. Contribution of the NOD1/CARD4 insertion/deletion polymorphism +32656 to inflammatory bowel disease in Northern Europe. Inflamm Bowel Dis 2007;13:882-9.
37. Van Limbergen J, Russell RK, Nimmo ER, et al. Tumour necrosis factor alpha promoter polymorphisms influence disease phenotype and severity in childhood inflammatory bowel disease. Gastroen-terology 2006;120:A-3.
38. Savage NW, Barnard K, Shirlaw PJ, et al. Serum and salivary IgA antibody responses to Saccharomyces cerevisiae, Candida albicans and Streptococcus mutans in orofacial granulomatosis and Crohn's disease. Clin Exp Immunol 2004;135:483-9.
39. Quinton JF, Sendid B, Reumaux D, et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cyto-plasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998;42:788-91.
40. Smith BR, Arnott ID, Drummond HE, et al. Disease location, anti-Saccharomyces cerevisiae antibody, and NOD2/CARD15 genotype influence the progression of disease behavior in Crohn's disease. Inflamm Bowel Dis 2004;10:521-8.
41. Klebl FH, Bataille F, Bertea CR, et al. Association of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies with Vienna classification subtypes of Crohn's disease. Inflamm Bowel Dis 2003;9:302-7.
42. Russell RK, Van Limbergen J, Drummond HE, et al. Disease phenotype but not genotype differs in children and adults with inflammatory bowel disease at diagnosis: analysis of more than 1500 patients from a homogenous patient cohort. J Pediatr Gastroenterol Nutr 2007;44:e17.
43. Van Limbergen J, Russell RK, Nimmo ER, et al. Autophagy gene ATG16L1 influences susceptibility and disease location but not childhood onset in Crohn's disease in Northern Europe. Inflamm Bowel Dis 2008;14:338-46.
44. Canani RB, Romano MT, Greco L, et al. Effects of disease activity on anti-Saccharomyces cerevisiae antibodies: implications for diagnosis and follow-up of children with Crohn's disease. Inflamm Bowel Dis 2004;10:234-9.
45. Gupta SK, Fitzgerald JF, Croffie JM, et al. Comparison of serolo-gical markers of inflammatory bowel disease with clinical diagnosis in children. Inflamm Bowel Dis 2004;10:240-4.
46. Kugathasan S, Collins N, Maresso K, et al. CARD15 gene mutations and risk for early surgery in pediatric-onset Crohn's disease. Clin Gastroenterol Hepatol 2004;2:1003-9.
47. Alvarez-Lobos M, Arostegui JI, Sans M, et al. Crohn's disease patients carrying Nod2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence. Ann Surg 2005;242:693-700.
48. Dubinsky MC, Lin YC, Dutridge D, et al. Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am J Gastroenterol 2006;101:360-7.
49. Beattie RM, Walker-Smith JA, Murch SH. Indications for investigation of chronic gastrointestinal symptoms. Arch Dis Child 1995;73:354-5.
50. Khan K, Schwarzenberg SJ, Sharp H, et al. Role of serology and routine laboratory tests in childhood inflammatory bowel disease. Inflamm Bowel Dis 2002;8:325-9.
51. Standaert-Vitse A, Jouault T, Vandewalle P, et al. Candida albicans is an immunogen for anti-Saccharomyces cerevisiae antibody markers of Crohn's disease. Gastroenterology 2006;130:1764-75.
52. Van Limbergen J, Russell RK, Nimmo ER, et al. Genetics of the innate immune response in inflammatory bowel disease. Inflamm Bowel Dis 2007;13:338-55.
53. Seibold F, Konrad A, Flogerzi B, et al. Genetic variants of the mannan-binding lectin are associated with immune reactivity to mannans in Crohn's disease. Gastroenterology 2004;127:1076-84.
54. Devlin SM, Yang H, Ippoliti A, et al. NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives. Gastroenterology 2006;132:576-86.
55. Joossens S, Reinisch W, Vermeire S, et al. The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology 2002;122:1242-7.